Hemispherx Biopharma, Inc. (NYSEAMERICAN:HEB) saw a large growth in short interest in the month of November. As of November 30th, there was short interest totalling 1,207,594 shares, a growth of 7.0% from the November 15th total of 1,129,042 shares. Based on an average daily trading volume, of 325,854 shares, the short-interest ratio is currently 3.7 days. Currently, 4.0% of the company’s shares are sold short.

An institutional investor recently raised its position in Hemispherx Biopharma stock. Vanguard Group Inc. increased its stake in Hemispherx Biopharma, Inc. (NYSEAMERICAN:HEB) by 0.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 453,805 shares of the specialty pharmaceutical company’s stock after purchasing an additional 2,709 shares during the period. Vanguard Group Inc. owned approximately 1.56% of Hemispherx Biopharma worth $227,000 as of its most recent filing with the Securities and Exchange Commission.

Shares of Hemispherx Biopharma (NYSEAMERICAN:HEB) traded down $0.03 during mid-day trading on Monday, hitting $0.33. 1,040,712 shares of the stock traded hands, compared to its average volume of 301,547. Hemispherx Biopharma has a one year low of $0.30 and a one year high of $0.93.

Hemispherx Biopharma (NYSEAMERICAN:HEB) last announced its quarterly earnings results on Wednesday, November 15th. The specialty pharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter. Hemispherx Biopharma had a negative net margin of 1,391.11% and a negative return on equity of 49.30%. The firm had revenue of $0.09 million during the quarter.

WARNING: This piece was first published by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/11/short-interest-in-hemispherx-biopharma-inc-heb-increases-by-7-0.html.

Hemispherx Biopharma Company Profile

Hemispherx Biopharma, Inc (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company’s segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon.

Receive News & Ratings for Hemispherx Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.